WINT — Windtree Therapeutics Income Statement
0.000.00%
- $1.90m
- -$0.65m
- 12
- 58
- 12
- 17
Annual income statement for Windtree Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.198 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 26.9 | 30.3 | 77.3 | 41.3 | 20.6 |
Operating Profit | -26.7 | -30.3 | -77.3 | -41.3 | -20.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -27.5 | -32.6 | -77.6 | -40.6 | -20.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -27.5 | -32.6 | -67.6 | -39.2 | -20.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -27.5 | -32.6 | -67.6 | -39.2 | -20.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -27.5 | -32.6 | -67.6 | -39.2 | -20.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2,115 | -1,872 | -1,395 | -759 | -4.45 |